Skip to main content
Premium Trial:

Request an Annual Quote

Auvation, ExpressOn Biosystems to Collaborate in Developing Anti-Cancer Targets

NEW YORK, Aug. 13 (GenomeWeb News) - Auvation, a Scottish company that focuses on developing biomarkers for tumors, and ExpressOn Biosystems, another Scottish company that focuses on the development of antisense RNA interference, have forged an agreement to collaborate in developing targets for cancer therapy, Auvation officials announced last week.


Financial terms of the deal were not disclosed.


According to the agreement, Auvation will provide up to 20 targets from their cancer market portfolio, and ExpressOn will use its ACCESSarray technology to determine regions on the corresponding RNA molecules that are optimally accessible to silencing reagents, which shut off the production of a target protein.


Auvation officials said their company will make upfront payments in return for access to ExpressOn's ACCESSarray technology.